130 related articles for article (PubMed ID: 9565062)
1. Retinopathy and tissue hexose in drug-treated animals.
Engerman RL; Kern TS
Arch Ophthalmol; 1998 Apr; 116(4):543-4. PubMed ID: 9565062
[No Abstract] [Full Text] [Related]
2. An aldose reductase inhibitor and aminoguanidine prevent vascular endothelial growth factor expression in rats with long-term galactosemia.
Frank RN; Amin R; Kennedy A; Hohman TC
Arch Ophthalmol; 1997 Aug; 115(8):1036-47. PubMed ID: 9258227
[TBL] [Abstract][Full Text] [Related]
3. Correction of early subnormal superior hemiretinal DeltaPO(2) predicts therapeutic efficacy in experimental diabetic retinopathy.
Berkowitz BA; Ito Y; Kern TS; McDonald C; Hawkins R
Invest Ophthalmol Vis Sci; 2001 Nov; 42(12):2964-9. PubMed ID: 11687543
[TBL] [Abstract][Full Text] [Related]
4. A biodegradable injectable implant sustains systemic and ocular delivery of an aldose reductase inhibitor and ameliorates biochemical changes in a galactose-fed rat model for diabetic complications.
Aukunuru JV; Sunkara G; Ayalasomayajula SP; DeRuiter J; Clark RC; Kompella UB
Pharm Res; 2002 Mar; 19(3):278-85. PubMed ID: 11934234
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes.
Gilbert RE; Vranes D; Berka JL; Kelly DJ; Cox A; Wu LL; Stacker SA; Cooper ME
Lab Invest; 1998 Aug; 78(8):1017-27. PubMed ID: 9714188
[TBL] [Abstract][Full Text] [Related]
6. Diabetic-like retinopathy ameliorated with the aldose reductase inhibitor WAY-121,509.
Robinson WG; Laver NM; Jacot JL; Glover JP; Basso MD; Blouin P; Hohman TC
Invest Ophthalmol Vis Sci; 1996 May; 37(6):1149-56. PubMed ID: 8631629
[TBL] [Abstract][Full Text] [Related]
7. The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in human diabetic retinas.
Murata T; Nagai R; Ishibashi T; Inomuta H; Ikeda K; Horiuchi S
Diabetologia; 1997 Jul; 40(7):764-9. PubMed ID: 9243096
[TBL] [Abstract][Full Text] [Related]
8. Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes.
Amano S; Yamagishi Si; Kato N; Inagaki Y; Okamoto T; Makino M; Taniko K; Hirooka H; Jomori T; Takeuchi M
Biochem Biophys Res Commun; 2002 Nov; 299(2):183-8. PubMed ID: 12437967
[TBL] [Abstract][Full Text] [Related]
9. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs.
Engerman RL; Kern TS
Diabetes; 1993 Jun; 42(6):820-5. PubMed ID: 8495805
[TBL] [Abstract][Full Text] [Related]
10. Response of capillary cell death to aminoguanidine predicts the development of retinopathy: comparison of diabetes and galactosemia.
Kern TS; Tang J; Mizutani M; Kowluru RA; Nagaraj RH; Romeo G; Podesta F; Lorenzi M
Invest Ophthalmol Vis Sci; 2000 Nov; 41(12):3972-8. PubMed ID: 11053301
[TBL] [Abstract][Full Text] [Related]
11. Abnormalities of retinal metabolism in diabetes or experimental galactosemia VIII. Prevention by aminoguanidine.
Kowluru RA; Engerman RL; Kern TS
Curr Eye Res; 2000 Oct; 21(4):814-9. PubMed ID: 11120572
[TBL] [Abstract][Full Text] [Related]
12. Increased H2O2, vascular endothelial growth factor and receptors in the retina of the BBZ/Wor diabetic rat.
Ellis EA; Guberski DL; Somogyi-Mann M; Grant MB
Free Radic Biol Med; 2000 Jan; 28(1):91-101. PubMed ID: 10656295
[TBL] [Abstract][Full Text] [Related]
13. Effect of ranirestat, a new aldose reductase inhibitor, on diabetic retinopathy in SDT rats.
Toyoda F; Tanaka Y; Ota A; Shimmura M; Kinoshita N; Takano H; Matsumoto T; Tsuji J; Kakehashi A
J Diabetes Res; 2014; 2014():672590. PubMed ID: 25215304
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor in diabetic retinopathy.
Tanaka Y; Katoh S; Hori S; Miura M; Yamashita H
Lancet; 1997 May; 349(9064):1520. PubMed ID: 9167467
[No Abstract] [Full Text] [Related]
15. Novel therapies to prevent diabetic retinopathy.
Skolnick AA
JAMA; 1997 Nov; 278(18):1480-1. PubMed ID: 9363954
[No Abstract] [Full Text] [Related]
16. Diabetic-like retinopathy: early and late intervention therapies in galactose-fed rats.
Robison WG; Jacot JL; Glover JP; Basso MD; Hohman TC
Invest Ophthalmol Vis Sci; 1998 Sep; 39(10):1933-41. PubMed ID: 9727416
[TBL] [Abstract][Full Text] [Related]
17. [Fidarestat (SNK-860)].
Hibi C
Nihon Rinsho; 2002 Sep; 60 Suppl 9():594-600. PubMed ID: 12387056
[No Abstract] [Full Text] [Related]
18. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo.
Joussen AM; Poulaki V; Qin W; Kirchhof B; Mitsiades N; Wiegand SJ; Rudge J; Yancopoulos GD; Adamis AP
Am J Pathol; 2002 Feb; 160(2):501-9. PubMed ID: 11839570
[TBL] [Abstract][Full Text] [Related]
19. Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells.
Hirata C; Nakano K; Nakamura N; Kitagawa Y; Shigeta H; Hasegawa G; Ogata M; Ikeda T; Sawa H; Nakamura K; Ienaga K; Obayashi H; Kondo M
Biochem Biophys Res Commun; 1997 Jul; 236(3):712-5. PubMed ID: 9245719
[TBL] [Abstract][Full Text] [Related]
20. [Potential pharmacological treatments for diabetic retinopathy].
Watanabe D; Takagi H
Nihon Rinsho; 2005 Jun; 63 Suppl 6():244-9. PubMed ID: 15999714
[No Abstract] [Full Text] [Related]
[Next] [New Search]
